Medication info

Telmisartan and Rosuvastatin Tablets 40/5 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Dong-Wha Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP*3)]
Approval status
Approval withdrawn

MFDS item code 202001856 · Approved 2020.03.17

This product's status changed to Approval withdrawn on 2024.04.09. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and dyslipidemia, suppression of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
In a drug interaction study of telmisartan 80mg and rosuvastatin 20mg, the active ingredients in this medication, telmisartan Cmax was approximately 0.87-fold and AUC approximately 1.00-fold in the presence of rosuvastatin, while rosuvastatin Cmax increased approximately 1.71-fold and AUC approximately 1.16-fold in the presence of telmisartan. Therefore, when administering this medication, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely. This medication is for use in adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medication produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medication is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medication to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL-cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL-cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering this medication at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medication is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
Dong-Wha Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, suppression of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
View approved original text

This medicine is used for patients who need to take telmisartan and rosuvastatin simultaneously. Telmisartan helps treat essential hypertension and reduce the risk of cardiovascular diseases. In particular, it reduces the risk of myocardial infarction and stroke in high-risk cardiovascular patients where ACE inhibitors cannot be used. Rosuvastatin is effective in treating hypercholesterolemia and dyslipidemia and is used as an adjunct when dietary management and exercise are insufficient. Additionally, it helps reduce the risk of cardiovascular diseases and slow the progression of atherosclerosis, thereby reducing the risk of stroke and myocardial infarction. This medication is used to improve cardiovascular health and reduce risks.

How to take

Adult dose

In a drug interaction study of telmisartan 80mg and rosuvastatin 20mg, the active ingredients in this medication, telmisartan Cmax was approximately 0.87-fold and AUC approximately 1.00-fold in the presence of rosuvastatin, while rosuvastatin Cmax increased approximately 1.71-fold and AUC approximately 1.16-fold in the presence of telmisartan. Therefore, when administering this medication, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely. This medication is for use in adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medication produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medication is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medication to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL-cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL-cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering this medication at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medication is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Precautions

This medication can cause serious harm to the fetus and newborn if used during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Individuals allergic to this medication or its components, women who are pregnant or may become pregnant, and breastfeeding individuals should avoid using it. Patients with severe liver function impairment or bile flow issues, those with muscle diseases, and patients with severe renal dysfunction should not use this medication. Elderly patients or those with high blood potassium levels, and patients with slightly impaired liver function should exercise special caution when using this medication. This medication can cause muscle pain, muscle weakness, and rarely severe muscle damage, so if any unusual symptoms occur in the muscles while taking this medication, consult a doctor immediately. As liver function abnormalities may occur, it is important to undergo liver function tests before and during treatment. This medication may interact with other drugs; thus, current medications should be disclosed to a doctor or pharmacist. Overdose may present with symptoms such as hypotension, dizziness, or acute renal failure, requiring immediate medical attention. Dizziness or drowsiness may occur while driving or operating machinery; caution is advised. Keep this medication out of reach of children and do not transfer it to another container.

Side effects

Headache, positional dizziness, sleep paralysis, hypertension, hypotension, low blood pressure, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, lung diseases, unspecified gastrointestinal disorder, benign gastrointestinal neoplasms, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver impairment, increased sweating, itching, rash, erythema, vascular edema, drug rash, toxic skin rash, eczema, urticaria, myalgia, lumbago, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, asthenia, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, hypoglycemia, vascular edema, hypersensitivity reactions including vascular edema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, oculobulbar weakness, headache, facial spasms, sensory changes, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, anorexia, arrhythmia, asthenia, edema, decreased libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechiae, palpitations, fatigue, nausea, inadequate response, cough, myalgia, increased CK, constipation, elevated AST, numbness, sensory changes, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, elevated ALT, myalgia, headache, increased CK, dizziness, constipation, elevated AST, asthenia, arthralgia, fatigue, numbness, sensory changes, chest discomfort, nausea, abdominal pain, diarrhea, anorexia, abdominal distension, pruritus, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. This storage method helps maintain the medication's effectiveness and safety for prolonged use.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.